PVRV

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, University of Peshawar

Conditions

Healthy Volunteers (Rabies Immunization)Rabies

Phase 3

Immunogenicity and Safety of Verorab® in a One-week Intradermal Post-exposure Prophylaxis Regimen

CompletedNCT01622062

Sanofi Pasteur, a Sanofi CompanyRabies

Start: 2012-06-29End: 2018-11-14Updated: 2022-04-25

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year

CompletedNCT03700242

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Rabies Immunization)

Start: 2018-09-26End: 2020-04-08Updated: 2022-04-25

Phase 4

Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally

CompletedNCT06433440

University of PeshawarRabies

Start: 2020-07-01End: 2021-08-30Updated: 2024-05-29

Related Papers

One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety

Vaccine2022-08-0111 citations

Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.

2020-04-095 citations

Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines

Vaccine2019-03-1614 citations